The performance of companies tied to flagship drugs like Viagra presents a nuanced investment landscape . While the initial boom of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the patent expiration in key regions has introduced substantial volatility. Investors are now grappling with the effect of generic